Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global recombinant protein market, by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), by Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), by End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 347.2 million in 2016 and is expected to exhibit a CAGR of 6.2% over the forecast period (2017-2025).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1516
Availability of large number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, coupled with increasing demand for biopharmaceutical products are the factors that are expected to drive growth of the recombinant protein market over the forecast period.
Moreover, key players are focusing on collaborations and acquisitions for drug discovery and development purposes. For instance, Crown Bioscience (CBI), Inc. entered into a collaboration with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. to develop CTLA-4 antibody, in 2017. Additionally, in 2016, CBI acquired PreClinOmics, Inc., an in vivo preclinical company that specializes in early research in cardiovascular and metabolic disease. Moreover, in the same year CBI launched six new recombinant cell lines, which include GITR, ICOS, CD137, CTLA-4, OX40, and RANK immune checkpoints and receptors for biological studies, drug discovery, and development. Furthermore, in 2012, ProSpec-Tany Technogene Ltd. and LifeMap Sciences, Inc., a wholly owned subsidiary of BioTime, Inc. entered into a definitive agreement to offer 1,000 recombinant proteins and antibodies, which can be used for stem cell research, drug discovery, and development biology. In addition, in 2014, BPS Bioscience, Inc. introduced 13 different mutant EZH2 complexes and two new assay kits for screening inhibitors of mutant EZH2.
Browse 39 Market Data Tables and 40 Figures spread through 151 Pages and in-depth TOC on Recombinant Protein Market, by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), by Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), By End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) – Global Forecast to 2025.
To know the latest trends and insights prevalent in the Recombinant Protein Market Press Release, click the link below: https://bit.ly/3mt8r6o
Additionally, major players of the market are focusing on expanding their geographic presence, in order to strengthen their market position. For instance, in 2016, Sigma Aldrich Company Ltd. established nine new M Lab Collaboration Centers in Asia Pacific, North America, Europe, and Latin America for its life science business. The centers are expected to fuel growth of its recombinant protein business. Moreover, manufacturers are increasingly participating in international and national conferences, in order to promote their products. For instance, Novoprotein Scientific, participated in AAPS National Biotechnology Conference, which was dedicated to recent developments of protein recombinants, globally in 2014. Moreover, in 2016, PeproTech, Inc. participated in Advances in Stem Cells and Regenerative Medicine conference held at EMBL, Heidelberg, Germany, in 2017. Furthermore, in 2016, Feldan Bio, Inc. and Elasmogen, a biopharmaceutical company signed an exclusive partnership for the development of intracellular biologics. Moreover, in 2017, BioVision Inc. launched Cas9 recombinant protein for genome editing. Cas9 protein of the CRISPR-Cas9 system is an RNA-guided DNA endonuclease enzyme, which aids in unwinding of genomic DNA complex.
Key Takeaways of the Recombinant Protein Market:
- The global recombinant protein market is expected to exhibit a CAGR of 2% over the forecast period (2017-2025), which is attributed to increasing product launches by market players such as BioVision, Inc., and HumanZyme, Inc.
- Recombinant protein market growth is attributed to increasing demand for recombinant protein in applications such as drug discovery & development and basic research
- Among product type, hormones segment is expected to exhibit significant growth over the forecast period, attributed to its increasing application in research and development of therapies for various metabolic disorders such as diabetes and others
- Among regions, Asia Pacific is expected to exhibit significant growth over the forecast period, owing to increasing activities such as research and development, and collaborations by market players in the region. For instance, in 2017, Amgen, Inc. entered into a collaboration with Simcere Pharmaceutical Group, a China-based company to develop four biosimilars for China market.
- Key players operating in the global recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1516
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027